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A line of FVB (H-2q) mice transgenic for the E6/E7 open reading frames of Human Papillomavirus type 16 driven from
the a-A crystallin promoter expresses E7 mRNA in lens and skin epithelium. E7 protein is detectable in adult skin, coinciding
with the development of inflammatory skin disease, which progresses to papillomata and squamous carcinomata in some
mice. By examining the outcome of parenteral immunization with E7 protein, we sought to determine whether endogenous
expression of E7 in skin had induced a preexisting immune outcome, i.e., specific immunity or tolerance, or whether the
mice remain naive (‘‘ignorant’’) to E7. Our data show that the antibody response to defined E7 B-epitopes, the proliferative
response to Th epitopes, and the delayed-type hypersensitivity (DTH) response to whole E7 did not differ between groups
of young and old E6/E7 transgenic mice (likely having different degrees of lifetime exposure to E7 protein) or between E6/
E7-transgenic and nontransgenic parental strain control mice. Although an E7-specific CTL response could not be induced
in the H-2q background of these mice, incorporation of a Db allele into the genome allowed comparison of Db-restricted
CTL responses in E6/E7 transgenic and nontransgenic mice. Experiments indicated that the E7-immunization-induced CTL
response did not differ significantly between E6/E7 transgenic and nontransgenic mice. We interpret these results to indicate
that in spite of expression of E7 protein in adult skin, E6/E7 transgenic mice remain immunologically naive (ignorant) of E7
epitopes presented by immunization. q 1997 Academic Press
INTRODUCTION and is limited to localized proliferating poorly differenti-
ated keratinocytes.
Human Papillomavirus type 16 (HPV 16) is tropic for Earlier work has shown that older #19 mice with skin
human anogenital epithelium and is associated with the disease, but not younger mice with phenotypically nor-
development of premalignant and invasive squamous mal skin, develop an antibody response to E7 and that
disease (Gissmann, 1992; Koutsky and Kiviat, 1993). In immunization with E7 results in an antibody response to
experimental systems, the products of the E6 and E7 viral the protein in #19 and FVB mice (Frazer et al., 1995). The
open reading frames (ORFs) are oncoproteins (Straight et former observation is probably a result of E7 protein from
al., 1995; McIntyre et al., 1996). damaged keratinocytes being taken up by ‘‘professional’’
A line of mice (denoted #19) transgenic for the HPV16 antigen presenting cells (Langerhan’s cells, dendritic
E6 and E7 ORFs driven from the aA crystallin promoter cells) and presented to the immune system. Prior to the
develops a skin pathology, including hair loss, dermal onset of inflammatory skin disease any presentation of
thickening, papilloma development, and eventual squa-
E7 protein is by keratinocytes (KC). In noninflamed skin,
mous cell carcinomata associated with increased levels
KCs express at the cell surface MHC class 1 but not
of E6 and E7 mRNAs (Lambert et al., 1993). E7 protein
class II molecules, and do not express the B7.1 (CD80)
was detected in normal and diseased skin in older mice
second signal molecule (Williams et al., 1994). While en-
(28 weeks) and was highest in skin tumors (Frazer et
dogenous peptide may be presented to the immune sys-al., 1995). No E7 protein was detected in skin samples
tem via class 1 in the absence of appropriate secondfrom young (7–13 week old) mice (limit of assay sensitiv-
signalling, the outcome may be tolerogenic rather thanity 0.05 ng E7/mg cellular protein; Selvey et al. 1994).
immunogenic (Bal et al., 1990). A further determinant ofExpression of E7 protein in the skin increases with age
immune outcome is the level of expression of antigen in
KCs; below a threshold of 100 molecules per cell, no
response (i.e., neither tolerance or immunity, but ‘‘igno-1 Present address: Sir Albert Sakzewski Virus Research Centre, Royal
Children’s Hospital, Herston Road, Herston Qld 4029 Australia. rance’’) is likely (Miller and Flavell, 1994).
2 To whom correspondence and reprint requests should be ad- This presentation is likely to model that which occursdressed at present address: Sir Albert Sakzewski Virus Research Cen-
in HPV16 /ve cervical carcinoma patients where thetre, Royal Children’s Hospital, Herston Road, Herston Qld 4029, Austra-
lia. Fax: /61-7-3253-1401. E-mail: r.tindle@mailbox.uq.edu.au. immune system is naive to E7 protein prior to HPV 16
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infection, and professional antigen presentation is only surface expression of Db in FACS analysis using antibody
28-8-6S (Ozato and Sachs, 1981).likely to occur following rupture of the basement mem-
brane and subepidermal tissue invasion by transformed
Immunization for antibodycells.
In this study we sought to determine whether constitu-
Groups of three to four #19 mice of ages 6, 11, 15, 23,
tive expression of E7 protein in skin in #19 mice had
27, and 32 weeks of age, and nontransgenic FVB control
induced E7-directed immunity or tolerance, or whether
mice aged 6 weeks were immunized intraperitoneally (ip)
the mice remain naive (ignorant) to E7. We did this by
(first immunization) and subcutaneously (sc) at the base
examining antibody production, the generation of T-prolif-
of the tail (second and third immunizations) with 50 mg
erative, delayed-type hypersensitivity (DTH), and T-cyto-
HPV 16 E7 as a glutathione S-transferase fusion protein
toxic (CTL) responses in #19 mice of various ages immu-
(E7.GST) / 10 mg Quil A adjuvant (Alonso de Velasco et
nized with E7 protein in comparison with E7 immunized
al., 1994) in saline, on Days 0, 21, and 98. Serum samples
nontransgenic (FVB) controls. We present evidence to
were prepared from retro-orbital plexus blood on Days
show: (1) antibody titers to major E7 B-epitopes elicited
0, 31, 98, and 105.
in response to E7 immunization did not differ significantly
among groups of #19 mice from 6–32 weeks of age or Antibody ELISA
between #19 mice and FVB nontransgenic controls. In
Sera were reacted at 377 for 45 min at a range ofaddition, antibody titers were not significantly different
dilutions in blocking buffer (PBS /5% skim milk / 0.1%between #19 mice of similar age with and without skin
Tween 20) with microtiter plate-bound E7 peptides 101,disease. (2) T-proliferative and DTH responses were sim-
104, and 106 (Fig. 1), which contain the strong B epitopesilar among #19 mice of varying ages and between #19
EYMLD, IDGP, and QAEPD, respectively (Tindle et al.,and similarly aged FVB control mice. (3) #19 and FVB
1990). Antibody binding was visualized in an ELISA reac-mice failed to make a CTL response to E7 immunogen,
tion using HRPO-linked Rabbit anti-mouse Ig (Silenussuggesting that no E7 CTL epitope recognised in the
Pty, Australia) plus ABTS (2, 21-azinobis (3-ethyl benzthia-context of MHC haplotype H-2Dq and Kq exists. However,
zoline) sulphonic acid) substrate as detecting reagentsboth #19 and FVB mice made transgenic for H-2Db and
as described (Tindle et al., 1990). Reactions were quanti-immunized with E7 protein displayed CTL responses di-
fied as optical density at 490 nM on a Titertek platerected to a Db-restricted E7 CTL epitope.
reader. Positive controls included monoclonal antibodiesThese data indicate that #19 mice, including those of
8F, 4F, and 6D specific for epitopes EYMLD, IDGP, andan age where E7 protein in skin is demonstrable, but no
QAEPD, respectively (Tindle et al., 1990).skin disease has developed, and those with overt skin
disease, remain naive to the B- and T-cell epitopes pre-
Delayed-type hypersensitivitysented to the immune system as a result of E7 immuniza-
tion.
Mice were immunized on Day 0 with 50 mg E7.GST /
The results have implications for (1) the presentation
10 mg Quil A or 50 mg GST / 10 mg Quil A in 100 ml
to the immune system of any non-self-antigen (e.g., viral,
saline sc at the base of the tail. Four hundred nanograms
tumor, or ‘‘altered-self’’) expressed in skin keratinocytes
of Pertussigen (Commonwealth Serum Laboratories Ltd.)
and (2) specific immune response development in recipi-
in 0.2 ml saline were injected intravenously (iv) immedi-
ents of E7-based therapeutic vaccines for E7 expressing
ately after immunization (de Moerloose et al., 1986).
HPV-associated cervical carcinoma.
Seven days later, mice under anesthesia were chal-
lenged in the pinna of the ear with 10 mg E7.GST (right
ear) and 10 mg GST (left ear) in a ca 10-ml volume. At 24MATERIALS AND METHODS
and 48 hr the thickness of each ear was measured at
Mice the site of injection with a spring-loaded micrometer. The
results are presented as ear thickness at 48 hr{ SD (ear
A line of mice, a A cry HPV 16 E6 E7. FVB, designated
thicknesses at 24 and 48 hr did not differ significantly). A
#19, are homozygous for a HPV 16 E6/E7 ORF transgene
positive control group of mice was immunized with 50
driven off an a-A crystallin promoter (Lambert et al.,
mg bovine serum albumin (BSA) / 10 mg Quil A and
1993). #19 and FVB parental strain mice (both H-2q), and
challenged with 60 mg BSA.
C57 BL (H-2b) mice were held under specific pathogen-
free conditions. Genetic purity was checked by isoen- T-proliferative response
zyme analysis. FVB mice transgenic for H-2Db (Azoulay
et al., 1994) were obtained from Dr. M. Brahic (Institut Groups of mice were immunized subcutaneously at
the base of the tail with 50 mg E7.GST protein, or aPasteur, Paris). #19/Db mice were obtained by crossing
FVB/Db with #19 mice. F1 offspring were obligate hetero- mixture of E7 peptides 103 and 106 (50 mg of each)
emulsified in Freund’s complete adjuvant (FCA, Difco, RAzygotes for the E7 transgene and express E7 protein in
skin. They were selected for the Db transgene by PBMC 137). Both these peptides contain strong T-proliferative
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epitopes active in the context of H-2q. Eight to ten days The cells were maintained in RPMI medium, supple-
mented with glutamine, pyruvate, HEPES buffer, and 10%later, mononuclear cells (LNC) were collected from ingui-
nal and periaortic lymph nodes and set up in culture in FBS. The cells grew as monolayers with a life span of
ca. 10 passages. For purposes of CTL assays, 104 cells96-well microtiter plates (Nunc) with peptides 103 or 106,
or with irrelevant peptide at 10 and 2 mg/ml as described were seeded in microtiter trays the day before assay.
Individual wells were labeled with 1 mCi 51Cr in situ and(Tindle et al., 1991). Assay groups were done in triplicate.
Four days later wells were pulsed with [3H]thymidine (100 washed prior to assay.
mCi) overnight. Cells were harvested onto filter mats and
Retroviral transfectionbound radioactivity was quantified by Beta-plate (Wallac)
scintillation counting. A positive control recall antigen Retroviruses recombinant for HPV16 E7 (PA317 E7)
was purified protein derivative (PPD) of tuberculin. Re- and HPV16 E6 (PA317 E6) were obtained from Dr. D.
sults were expressed as a stimulation index (SI)  mean Galloway (Fred Hutchinson Cancer Center, Seattle).
cpm from wells with experimental peptide divided by Cell lines were infected and selected in 500 mg/ml
mean cpm from wells with irrelevant peptide. Geneticin as described (Demers et al., 1994). The pres-
ence of the E7 DNA in infectants was confirmed by
Cytotoxic T-cell responses
PCR of total cellular DNA using primer pairs yielding
full-length E7. The PCR product was dot-blotted ontoInduction of CTL and CTL assay. Mice were injected
nitrocellulose and probed by nucleic acid hybridizationintradermally (id) in each of the hind footpads with 50 ml
using a 32P-end-labeled oligonucleotide spanning E7PBS containing 50 mg E7.GST protein or 106 peptide plus
bases 689 – 755. Negative controls for E7 included cel-10 mg Quil A. Four days later, popliteal and inguinal lymph
lular DNA and nontransfected cells. Following appro-nodes were excised and LNC were cultured at 3–5 1
priate stringency washes, blots were subject to autora-106 cells per 2 ml plus 30 U/ml recombinant human IL-
diography using X-omat film (Kodak).2 (Gibco BRL) in a 24-well plate. After 4 days in culture,
LNC were harvested, washed, and set up in microtiter
Hybridoma CTL target cells expressing H-2qwell culture with 5 1 103/well 51Cr-labeled target cells
and H-2Db(below) at effector cell: target cell ratios of 40:1 and 4:1.
Supernatants were harvested 4.5 hr later and 51Cr re- Spleen cells from C57-BL6 (H-2b) 1 FVB (H-2q) F1 hy-
lease was quantified by g-counting. Results are ex- brid mice were fused with Sp20 myeloma cells using
pressed as percentage of specific cytotoxicity  a 0 standard polyethylene glycol (PEG)-mediated procedures
b, where a  (51Cr release in experimental well minus (Campbell, 1980) and selection in HAT medium. Twelve
background)/(detergent mediated total 51Cr release mi- hybridomas were cloned twice by limiting dilution. All
nus background) 1 100%; b  (51Cr release from targets screened positive for cell-surface expression of H-2Db,
without E7 peptide or E7 gene minus background)/(total Dq, and Kq using monoclonal antibodies 28-8-6S, KH117,
release 0 background) 1 100%. and KH114 (Pharmingen), respectively, in standard FACS
Target cells. Target cells (106) in 100 ml supplemented analysis. Two hybridomas were selected for infection
DMEM / 10% FBS were labeled for 60 min with 100 with Retrovirus E7 (above). One infected hybridoma con-
mCi51Cr (Na chromate; Amersham), and washed twice taining the E7 gene and denoted ICI-2C-Ret E7 was se-
using FBS underlay. One hundred microliters containing lected as a target cell for H-2Db and H-2q-restricted CTL
5 1 103 cells were dispersed into microwells. In the case lysis.
of peptide pulsed cells, microwells contained 20 ml of
predispensed peptide in tissue culture medium to give RESULTS
a final concentration of 10 mM. Plates were incubated
Antibody response following E7 immunization in #19for 1 hr at 377 to allow target cells to become ‘‘sensitized’’
mice of varying agesby peptide-MHC class I interaction, before addition of
effector cells. Controls for the assay included targets
At Day 31 after immunizations with E7.GST on Days 0
without effectors (‘‘background release’’), nonsensitized
and 14, the sera of #19 mice of all age groups tested
targets, and in some assays, target cells with ‘‘irrelevant’’
displayed high titer antibody to peptides 101, 104, and
effector cells.
106 (Fig. 1) containing the three major E7 epitopes
EYMLD, IDGP, and QAEPD, respectively (Fig. 2). (TheCell lines from E7 transgenic mouse epithelium
titer varied among antibodies to the three peptides being
highest for peptide 101 and lowest for peptide 106; opti-Cell lines T93 and 1022.16 were derived from aA cry
HPV16 E6/E7 transgenic mice. T93 was derived from a cal density readings at serum dilutions 1/12,800 (peptide
101), 1/3,200 (peptide 104), and 1/1,600 (peptide 106)spontaneous epithelial tumor and 1022.16 was derived
from a tumor that arose in a FVB mouse injected with were used to compare groups.) In all age groups the
antibody response declined by Day 98, but was recalledcells established in tissue culture from aA cry HPV16
E6/E7 transgenic mouse lens tissue (Griep et al., 1993). by a third immunization on Day 98 (measured as eleva-
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FIG. 1. Overlapping peptides spanning the HPV16 E7 protein. (Peptides were synthesized with unblocked ends in our laboratory using 9-
fluorenylmethoxycarbonyl (Fmoc) chemistry on an Applied Biosystems 431A peptide synthesiser. The HPLC profile, amino acid composition, toxicity
and mitogenicity of all peptides was checked.) Linear B-epitopes (Tindle et al., 1990) are boxed. An immunodominant T-helper epitope (Tindle et
al., 1991) is underlined (solid). A Db-restricted CTL epitope (Feltkamp et al., 1993) is underlined (dashed).
tion of OD by Day 105). This pattern of response was Delayed-type hypersensitivity response to HPV16 E7
similar to that displayed by FVB nontransgenic parental
Three groups of #19 mice aged 13, 28, and 37 weeks,mice. The sera of E7-immunized #19 and FVB mice did
and age-matched FVB controls were immunized withnot react with peptides spanning other regions of the
E7.GST fusion protein in Quil A adjuvant and 7 days laterE7 molecule (data not shown). The sera of #19 mice
challenged intradermally in the ear-lobe with E7.GST fu-immunized with adjuvant / saline alone gave negligible
sion protein (left ear) and GST alone (right ear). A DTHOD readings.
response was measured by ear thickness increment at
48 hr. #19 mice of all ages showed augmented ear thick-Antibody response following E7 immunization in #19
ness in the E7.GST challenged ear compared to the GSTmice with and without skin disease
challenged ear, indicating an E7 specific component to
The timing of the spontaneous onset of skin disease the response. No significant differences in thickness in-
among individual #19 mice is variable. In the above ex- crement in the E7.GST challenged ears were observed
periment, some mice in the older age groups already between the three age groups of #19 mice, nor between
displayed skin disease at the time of first immunization #19 mice and FVB mice of corresponding age (Fig. 3).
or had developed it by the time of the first bleed (Day 31
post-first-immunization). Others remained disease free at T proliferative response
Day 31. Among mice from the younger age groups (and
those from the older age groups which had not devel- LNC from groups of FVB mice immunized with overlap-
ping peptides spanning the entire E7 molecule (Fig. 1)oped skin disease at Day 31), many had developed skin
disease by Day 105 post-first-immunization while others proliferated when recalled in vitro with peptides 103 and
106 but not with the other peptides (data not shown).had not. We thus analyzed the data from the above exper-
iment to compare serum antibody response in mice with Thus within the context of peptide immunization, pep-
tides 103 and 106 contain major proliferative epitopesand without skin disease at Day 31 and in mice with and
without skin disease at Day 105 (Table 1). recognized in the context of H-2q. LNC from FVB mice
immunized with E7.GST protein proliferated in vitro inRead-outs using sera from #19 mice presenting with
skin disease at Day 31 did not differ significantly from response to 103 but not 106 or other peptides of the
series. (Stimulation index of 2.9I at 10 mg/ml in vitro recallthose of #19 mice without skin disease at Day 31 in
the magnitude of the serum antibody response following peptide 103).
To evaluate whether E7 protein expressed in skin inimmunization with E7 against peptides 101 and 104 mea-
sured on Day 31, and against peptides 101, 104, and #19 mice engendered an endogenous T proliferative re-
sponse, LNC cells from groups of #19 mice of various106 measured on Day 105 (students t test). A marginally
significant difference was observed in reactivity to pep- ages (and FVB mice of similar ages as controls) not
immunized with E7 or E7 peptide were challenged intide 106 on Day 31 (t  3.602, P  0.0024). #19 mice
presenting with skin disease at Day 105 did not differ vitro with peptide 103. No proliferative response to pep-
tide 103 was observed in any of the age-groups of #19significantly from mice without skin disease at Day 105
in the magnitude of the serum antibody response against mice (Fig. 4.1).
To evaluate whether E7-peptide immunized #19 micethe three peptides measured on Day 105.
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Cytotoxic T-cell (CTL) response
In preliminary experiments it was determined that
E7.GST-immunized FVB mice failed to kill E7-DNA con-
taining cell lines T93 and 1022.16 established from a-A
cry HPV16 E6/E7 transgenic mice, although these lines
were killed in allo-CTL reactions and were, therefore, in
principal susceptible to effector-mediated lysis in 51Cr
release assays (data not shown). In further experiments
we augmented the amount of E7 protein in these cells
to levels detectable in an E7 protein capture assay (Sel-
vey et al., 1994) by infection with recombinant Retrovirus
E7. The resultant T93.Ret E7 and 1022.16.Ret E7 cells
expressed 48.5 ng E7/mg and 76.7 ng E7/mg total cellular
protein, respectively. These E7 expressing cells were not
killed by effectors from E7 immunized H-2q mice. T93 and
1022.16 cells pulsed with overlapping peptides spanning
the entire E7 molecule were not killed by effectors from
E7 immunized H-2q mice or H-2q mice immunized with
groups of these peptides (not shown). All of these experi-
ments contained a positive control arm to confirm the
efficacy of the immunization and experimental proce-
dures used: E7-expressing or E7 peptide pulsed H-2b
targets (EL4.C2 (Tindle et al., 1995) and EL4 cells, respec-
tively), were killed by effectors from E7.GST immunized
H-2b (C57 BL6) mice or effectors from H-2b mice immu-
nized with peptide 106 containing the H-2Db restricted
CTL epitope RAHYNIVTF.
We inferred from these experiments that HPV16 E7
protein does not contain a CTL epitope recognized in the
context of H-2q. To investigate this further we constructed
cells expressing both H-2q and H-2Db restriction ele-
ments and E7 protein, as follows. B-cell hybridomas were
derived from spleen cells of H-2q 1 H-2b (FVB 1 C57 BL)
F1 hybrid mice and were infected with Retrovirus E7.
Hybridoma ICI-2C-Ret E7, demonstrably expressing H-
2Dq, H-2Kq, and H-2Db at the cell surface, and containing
the E7 gene (Fig. 5), and IC-2C (not infected with Retrovi-
FIG. 2. ELISA reactivity of sera from #19 mice of varying ages as rus E7) were used as targets for CTL assays. ICI-2C-Ret
indicated and FVB mice of 6 weeks of age, immunized with E7.GST E7 was specifically killed by effector cells from E7.GST
protein / Quil A (arrows indicate times of immunization) against three immunized H-2b (C57 BL6), but not H-2q (FVB) mice (Figs.
HPV16 E7 peptides, each containing a major B-epitope. QA denotes
6A and 6B). In addition, FVB H-2q effector cells failed to#19 mice (6 weeks old) immunized with Quil A alone.
kill ICI-2C pulsed with any of the peptides covering the
entire E7 molecule, while control H-2b effectors killed ICI-
2C pulsed with peptide 106 containing the H-2b-restrictedwould mount T-proliferative response to peptides 103
CTL epitope RAHYNIVTF (percentage of specific lysis atand 106 comparable to those in nontransgenic FVB mice,
40:1 target: effector ratio 23.5{ 0.7% (ICI-2C/ peptideand whether there might be age-related differences
106), 11.1 { 0.9% (ICI-2C / irrelevant peptide).among #19 mice, groups of #19 mice, and FVB controls
These results suggest most strongly that the H-2qof various ages were immunized with a 103/106 peptide
background of FVB and #19 mice does not permit themix, and 8–10 days later, LNC were challenged in vitro
recognition of a CTL epitope in E7 protein.with peptides 103 or 106 or irrelevant control peptide
Thus, in order to investigate CTL responses in #19(Fig. 4.2). No significant differences in proliferative re-
mice induced by immunization with E7, we introducedsponses to peptides 103 were detected among groups
the Db restriction element of the known E7 CTL epitopeof #19 mice of 7, 32, and 46 weeks of age. Similarly no
RAHYNIVTF into the H-2q background of #19 mice, bysignificant differences in LNC proliferation were detected
crossing to the F1 generation with a line of FVB micebetween #19 mice and that of nearest-age FVB controls.
Similar observations were made for 106 peptide. transgenic for H-2Db. The resultant mice were denoted
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TABLE 1
Antibody Response to HPV16E7 Peptides in E7 Immunized #19 Mice with and without Skin Disease: Serum ELISA Reactivity vs E7 Peptides
Day post first immunization
Day 31 Day 105
peptide peptide
101a 104b 106c 101a 104b 106c
Without skin diseased 0.8 { 0.14 0.31 { 0.29 0.17 { 0.19 0.85 { 0.21 0.40 { 0.41 0.17 { 0.07
(n  14)
With skin diseased 0.97 { 0.50 0.61 { 0.41 0.72 { 0.48 0.86 { 0.54 0.32 { 0.31 0.29 { 0.38
(n  4)
ns ns t  3.602 ns ns ns
P  0.0024
Without skin diseasee 0.55 { 0.28 0.14 { 0.08 0.11 { 0.07
(n  3)
With skin diseasee 0.43 { 0.21 0.15 { 0.11 0.24 { 0.2
(n  5)f
ns ns ns
a OD 280 at 1:12,800 dilution, mean { standard deviation.
b At 1:3,200 dilution.
c At 1:1,600 dilution. [Note: These dilutions are end titers reflecting the strength of the responses to epitopes contained in peptides 101, 104, and
106 in H-2q mice.]
d At Day 31 post first immunization.
e At Day 105 post first immunization.
f Note that the group of mice presenting with skin disease at Day 105 includes those mice which already developed skin disease by Day 31.
#19/Db. Effector cells from E7 immunized #19/Db mice E7.GST immunized FVB/Db (H-2q, Db) but not FVB (H-2q)
mice were obtained. (not shown).specifically killed EL4 (H-2b) cells pulsed with peptide
106 containing the RAHYNIVTF CTL epitope, but not EL4
cells pulsed with irrelevant peptide (Fig. 6C). The effector DISCUSSION
cells also killed Db targets expressing the E7 gene (1C1-
2C-Ret-E7 cells) (Fig. 6D). Results demonstrating a posi- The E7 oncoprotein of HPV 16 transforms KCs of ano-
genital epithelium resulting in anogenital cancer. E7 pro-tive E7-directed CTL response of similar magnitude in
FIG. 3. DTH response evoked by intradermal ear challenge in HPV16 E7.GST-immunized #19 and FVB mice of various ages. Results are expressed
as ear-thickness (mm) { SD. Open symbols, mice challenged with E7.GST. Closed symbols, mice challenged with GST. Mean ear thickness of GST
immunized #19 mice challenged with E7.GST was 35.7 { 8.15 mm. (Ears were measured at 24 and 48 hr. Only 48-hr data are shown.)
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FIG. 5. A B-cell hybridoma, IC1-2C, derived from (H-2b 1 H-2q) F1
hybrid spleen cells expresses at the cell surface (A) Kq; (B) Dq; and (C)
Db (shaded); and (D) when infected with rRetrovirus E7, contains E7
DNA: In (A) and (B), cells were reacted with biotinylated anti-mouse
Kq and Dq MAbs and visualized in FACs analysis using Streptavidin-
phycoerythrin (Caltag). In (C), cells were reacted with anti-Db murine
Mab (IgG2a) and visualized in FACs analysis with FITC-anti-mouse IgG2a
(Silenus). Negative controls included ICI-2C cells stained with irrelevant
antibody, and also, irrelevant cells (H-2d Sp20 mouse myeloma) stained
with anti-Kq, Dq, and Db Mabs. (D) DNA from hybridomas ICI-2C and
2B4, and ICI-2C, infected with rRetrovirus-E7 or E6, and E7-containing
plasmid controls were amplified in PCR with E7 primers, dot-blotted
onto nitrocellulose, and probed with a 32P-labeled E7 oligonucleotide
probe. (1) ICI-2C; (2) ICI-2C Ret E6; (3) ICI-2C Ret E7; (4) 2B4; (5) pHPV16
0.02 mg; (6) pJ4omega E7; (7) pHVP16 0.02 mg; (8) No DNA.
FIG. 4. T-proliferative responses. (4.1) LNC from mice #19 and FVB
tein exerts its effect by combining with and abrogatingmice of various ages immunized with saline:Freund’s complete adju-
vant (FCA) were cultured for 4 days in the presence of 10 mg/ml (left the cell-cycle regulatory effect of the retinoblastoma pro-
bar of a pair) or 1 mg/ml (right bar of a pair) of peptide 103. Proliferation tein (RB) (Slebos et al., 1994). A corollary is that E7 protein
was quantified by [3H]thymidine incorporation. Results are expressed must persist if cells are to remain transformed (von
as a stimulation index (see Materials and Methods). Open bars, FVB
Knebel Doeberitz et al., 1994). E7 protein thus functionsmice; stippled bars, #19 mice; solid bars, FVB mice which had been
as a tumor-associated antigen to which therapeutic vac-immunized with 100 mg of a 50/50 mix (w:w) of peptides 103 and 106
in FCA and recalled with 10 mg/ml peptide 103 (positive control). Me- cine strategies may be directed. That the immune re-
dium and irrelevant peptide controls were in the range 7,000–18,000 sponse, particularly if augmented by vaccination, might
counts per minute (cpm) and 11,500–22,000 cpm, respectively; PPD serve to control disease is indicated by worsening out-
positive controls were in the range 340,000–428,000 cpm. (4.2) LNC
comes of HPV infection in constitutively or iatrogenicallyfrom #19 mice (open bars) and FVB mice (stippled bars) immunized
immunosuppressed individuals (see Tindle and Frazer,with 100 mg of a 50:50 (w:w) mix of peptides 103 and 106 in FCA were
cultured for 4 days in the presence of 10 or 1 mg/ml of peptide 103 1994 for review), and by the control by E7 immunization of
or 106. Proliferation was quantified by [3H]thymidine incorporation. E7 containing tumour growth in animal tumor challenge
(A) LNC from 103/106 immunized #19 mice recalled with peptide 106;
models (Chen et al., 1992; Feltkamp et al., 1993; Tindle(B) LNC from 103/106 immunized #19 mice recalled with peptide 103;
et al., 1995).(C) LNC from 103/106 immunized FVB mice recalled with peptide 106;
(D) LNC from 103/106 immunized FVB mice recalled with peptide 103. Papillomavirus infection presents a natural model for
Results are expressed as stimulation index { standard deviation. Me- the study of immune activation by, and immune recogni-
dium alone and irrelevant-peptide negative controls gave counts in tion of, epithelial cells presenting non-self-antigen. HPVs
the range 1,200–5,000 cpm and 2,600–8,200 cpm, respectively. PPD-
are obligatory epitheliotropic (Pfister, 1984). Unlike otherpositive controls gave counts in the range 260,000–357,000 cpm. #19
known epitheliotropic viruses (herpes simplex, pox vi-and FVB mice immunized with adjuvant alone gave stimulation indices
2, after LNC challenge with peptides 103 or 106. ruses), HPVs do not kill the KCs which they infect: rather
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FIG. 6. CTL lysis of targets measured by 51Cr-release assay. CTL from (A) FVB (H-2q) mice, (B) C57 BL (H-2b) mice immunized with E7.GST /
Quil A (solid line) or Quil A alone (dashed line) versus B-hybridoma ICI-2C (Kq/, Dq/, Db/) (closed squares) or ICI-2C-Ret E7 (open squares) targets.
(C) CTL from #19/Db (H-2q, Db) mice immunized with E7.GST / Quil A versus EL4 (Db/) targets pulsed with irrelevant peptide (closed square), or
EL4 pulsed with peptide 106 containing the Db-restricted CTL epitope (open triangle), or transfected with E7 gene (EL4.C2) (open square). (D) CTL
from #19/Db mice immunized with E7.GST / Quil A (solid line) or Quil A alone (dashed line) versus ICI-2C hybridoma (closed symbols) or ICI-2C-
Ret E7 (open symbols) targets. Results are expressed as means { SD of triplicate samples.
the infected KCs mature and are desquamated, complete #19 mice transgenic for the HPV16 E7 ORF provide
a means to investigate E7 antigen presentation to thewith viral particles. As a result there is little or no extracel-
lular release of viral proteins for presentation to the im- immune system. In these mice, there is no expression
(RT-PCR) of E7 in the thymus (Lambert et al., 1993) andmune system by MHC class 2 molecules on professional
APCs (Langerhans cells). Furthermore, no inflammatory therefore, the mice escape central tolerization to E7 pro-
tein (Frazer et al., 1995). E7 protein is first detected inresponse occurs in HPV-infected epithelium thus obviat-
ing cytokine mediated induction of MHC class 2 mole- noninflamed, ‘‘normal’’ skin, and this precedes the devel-
opment of inflammatory skin disease (beginning at ca.cules on the surface of infected KCs, and there may be
no induced secondary signals from KCs or Th cells for 12 weeks of age) in which E7 protein expression is high-
est, and invasive squamous tumors.cytotoxic T cell (CTL) activation.
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It is pertinent to examine the outcome of E7 presenta- #19 mice cannot be detected (R. Azoury, unpublished).
Further experiments in our laboratory indicate that #19tion to the immune system prior to inflammatory skin
disease since this sheds light on the efficacy or other- mice appropriately immunized with E6 fusion protein
make E6-specific antibody, T-proliferative, and DTH re-wise of KCs to induce a (negative or positive) immune
response, with implications for any non-MHC antigen sponses in the same manner as identically immunized
nontransgenic controls (R. Azoury, unpublished). Thus,presented through skin as a result of infectious agents,
tumorigenesis, or the appearance of autoantigens. The even if E6 protein is produced in the skin, #19 mice
remain positively immunologically responsive to the epi-chronology of E7 protein putative exposure to the im-
mune system in #19 mice has parallels with that which topes presented by E6 immunization. This parallels the
E7 responsiveness of E7-immunized #19 mice.occurs in progressing HPV16-associated lesions of hu-
man cervical epithelium. Here, E7 is expressed in an No CTL response measurable against E7-containing
H-2q target cells could be induced in #19 mice or FVBintact noninflamed epithelium, prior to progression to
preneoplastic and neoplastic lesions which coincide [at mice immunized with whole E7 protein or any of a series
of generously overlapping peptides spanning the entireleast in 20–60% of patients (Jochmus-Kudielka et al.,
1989; Garenstroom et al., 1994)] with the appearance of E7 molecule, using experimental conditions which rou-
tinely induced a good CTL response in C57 (H-2b) mice.E7-specific serum antibody.
In the present study, we compared the outcome of This observation suggests that there is no CTL epitope
in E7 protein recognized by mouse CTL precursors inimmunization with E7 protein in young #19 mice at an
age at which E7 protein could not be detected in skin, the context of H-2Kq and Dq. Two pieces of data add
weight to this surmise; (1) (hybridoma) target cells shownwith older #19 mice displaying E7-associated skin phe-
notype, and with syngeneic nontransgenic FVB control to coexpress both H-2q and H-2b at the cell surface, were
killed by effectors from H-2b E7-immunized mice, but notmice. We hypothesized that the outcome of the E7 protein
immunization would reflect the immunological status, i.e., from H-2q E7-immunized mice when these target cells
were made to express whole E7 (by Retrovirus E7 trans-tolerant, versus immune versus ‘‘naive’’ of the mice with
regard to E7. fection), or were pulsed with E7-peptides, and (2) LNC
from E7-immunized #19 or FVB mice made cotransgenicWe have previously shown that E7 immunized #19
mice exhibited E7-specific serum antibody responses for H-2Db specifically killed the H-2b, H-2q expressing
target cells (but not targets expressing H-2q alone)(Frazer et al., 1995). In this paper we show that irrespec-
tive of age (and therefore presumably degree of life-time pulsed with a peptide containing the Db-restricted CTL
epitope. This latter observation suggests that exposureexposure to endogenous E7 protein) and skin phenotype
(normal vs diseased), E7-immunized #19 mice show E7- to E7 expressed in skin had not rendered anergic E7-
directed CTL precursors in #19/Db mice (which constitu-directed antibody responses, DTH responses, and T-pro-
liferative responses of similar magnitude and, in the case tively express both Db and E7.) (It also obviates the possi-
bility of a constitutive inability of #19 and FVB to mountof antibody, of similar chronology. Furthermore, no con-
sistent differences were detected between these re- CTL responses as an explanation for the lack of CTL
response to E7 in these mice).sponses and those exhibited by identically immunized
FVB nontransgenic control mice. No responses to the B- We report that immunization of #19 mice (with or
without skin disease) produces an antibody responseand T-epitopes we examined were seen in unimmunized
#19 mice. These data argue that the immune system of directed to the N* terminus of the E7 molecule. (Note
in addition that antibody titers were highest against#19 mice prior to immunization with E7 protein, has not
encountered, i.e., is naive to, the E7 B- and T-epitopes the most N* terminal peptide (101) and lowest against
the least N* terminal peptide (106)). We have earlierinvolved in these responses. The epitopes constitute the
major epitopes recognized by B- and T-repertoires of reported that unimmunized #19 mice with skin disease
(but not unimmunized #19 without skin disease) spon-mice of a variety of MHC haplotypes (Tindle et al., 1991).
One would not expect #19 mice to be centrally tolerant taneously develop antibody to the C* terminal end of
the E7 molecule (Frazer et al., 1995). We hypothesizeto E7 protein since it is not expressed perinatally in the
thymus nor at any immunologically accessible site. In that E7 protein expressed in the skin is not perceived
by the immune system until the development of inflam-this study we found no evidence for the acquisition of
peripheral tolerance to E7 protein in #19 mice with age matory skin disease when (a) upregulation of MHC
class 2 on keratinocytes may occur as a result of in-as measured by specific antibody production, DTH, and
T-proliferation. flammation (Gaspari and Katz, 1995) allowing presen-
tation to CD4 T-cells of processed endogenous proteinAlthough HPV16 E6 mRNA occurs in adult epithelium
in #19 mice (Lambert et al., 1993) E6 protein has not including E7, and (b) E7 is liberated from ruptured kera-
tinocytes, and may be taken up by local ‘‘professional’’been detected. This may represent a lack of appropri-
ately sensitive immunodetection reagents and assay, antigen presenting cells (LCs).
This surmise is reinforced by the observation that #19rather than absence of specific protein translation. How-
ever, spontaneous antibody response to E6 protein in mice which are heterozygous for the E7 gene and which
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do not acquire skin disease (see below), although they B- and Th-cells specific for epitopes presented by E7
immunization, (2) Th and B cells are activated by immuni-express E7 protein in skin, do not develop a spontaneous
antibody response to endogenous E7 (R. Tindle, unpub- zation with E7 protein, (3) E7 expression in normal skin
does not functionally abrogate the recall of E7-specificlished).
Reactive T-cells in the periphery may ignore cognate Th or TDTH cells, or of memory B cells. (4) There is an
absence of an E7-directed CTL response restrictedantigen if (1) antigen bearing cells are sequestered at a
site anatomically impervious to T-cells; (2) antigen bear- through H-2q. Incorporation of a suitable restriction ele-
ment (Db) into the genome allows a CTL response di-ing cells express few or no MHC or costimulatory mole-
cules necessary to activate T-cells [e.g., B7.1 (Williams rected to a Db restricted CTL epitope to be induced by
immunization in both #19/Db and FVB/Db mice. That suchet al., 1994)] or; (3) reactive T-cells are peripherally de-
leted or anergized by interaction with antigen bearing a response can be engendered in #19/Db mice indicates
that low levels of E7 expression in phenotypically normalcells. A number of transgenic models address these is-
sues, and while the determinants of outcome (i.e., na- skin does not serve to render CTL precursors anergic.
The inference drawn in this paper that E7 expressedivety, tolerance, or immunity) are not fully understood, it
is clear that timing and level of expression and availabil- in skin keratinocytes may not be presented to the afferent
arm of the immune system in such a way as to induceity of costimulatory signals are important parameters.
Thus, deletional B and/or T tolerance ensues from high a (positive or negative) response receives support from
further work in our laboratory showing that FVB mice faillevel of transgenic protein expression in multiple tissues,
whereas naivety or developing immunity is a likely out- to reject E7 expressing skin grafts from #19 mice (L.
Dunn, submitted).come where transgene expression is lower grade and
tissue specific (reviewed in Miller and Flavell, 1994), as The studies reported here are relevant to the immuno-
logical outcome of any non-MHC, non-self-protein ex-it is in the case of E7 and #19 mice.
The inability of H-2q mice to mount an E7-directed CTL pressed in epithelial cells, with implications for viral in-
fection, tumor development, and autoimmunity. There isresponse, reported here, is consistent with the finding
that depletion of CD8/ cells fails to alter the onset of also relevance to the development of tumor vaccines, in
particular to the application of E7-based vaccines forskin disease in these mice (Hilditch et al., submitted). An
active CTL response is coincident with rejection of skin HPV E7-expressing cervical carcinoma.
allografts (reviewed in Strom et al., 1996) and tumors
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